CDK4 and neoplasm: Combination therapy of CDK4/6 inhibitors with immune checkpoint blockade has been shown to increase anti-tumor efficacy in preclinical models (Goel et al., 2017; Deng et al., 2018) and provides the rationale to evaluate this combination clinically.